To evaluate the in vivo antitumor efficacy of NKG2D/CD28&CAR-T cells, we established mouse tumor models using fluorescently-labeled cell lines for both solid and hematological tumors. Here, CD28 is linked to hematopoietic and lymphoid cell neoplasm.